Overview
JAK-STAT-GO: Personalized, Targeted Therapy Options for Your IBD Patients
Click the"View Activity" button to view this activity.
View ActivityCME/CE no longer available for this activity
How can clinicians know they have current information for improving patients’ IBD outcomes? Expert faculty from the Icahn School of Medicine at Mount Sinai, University of Chicago Medicine and Biological Sciences, and Montefiore Medical Center/Albert Einstein College of Medicine recently led a symposium at Digestive Disease Week® (DDW) 2019 exploring the latest in treat-to-target paradigms, the role of the JAK-STAT pathway, and related research on investigational JAK inhibitors in IBD treatment. Video excerpts from the symposium are available as modules making it easier for the learner to move easily from one excerpt to another.
This activity is intended for gastroenterologists, and other allied health care professionals interested in the JAK/STAT signaling pathway and applications to treatment of IBD
Clinicians who treat patients with inflammatory disease such as IBD need to be updated on new and emerging therapies that will lead to individualized treatment and improved outcomes. Specifically, clinicians require education surrounding the role of the JAK/STAT signaling pathway in immune mediated diseases, up-to-date knowledge of the efficacy and safety of investigational JAK inhibitors, and the role of new and emerging JAK inhibitors in the treatment paradigm in IBD.
Upon completion of this activity, participants will be able to:
• Discuss the role of the JAK/STAT signaling pathway in the pathogenesis of IBD and the rationale for inhibition
• Compare and contrast the cytokine pathways targeted by available and emerging JAK inhibitors in IBD
• Interpret the clinical trial efficacy and safety data of JAK inhibitors investigated for Crohn’s disease and ulcerative colitis
• Identify IBD patients who require a change in therapy
• Discuss the role of the JAK/STAT signaling pathway in the pathogenesis of IBD and the rationale for inhibition
• Compare and contrast the cytokine pathways targeted by available and emerging JAK inhibitors in IBD
• Interpret the clinical trial efficacy and safety data of JAK inhibitors investigated for Crohn’s disease and ulcerative colitis
• Identify IBD patients who require a change in therapy
Video module highlights includes:
• What’s New in IBD Care? Choosing Targets and Selecting Therapy
• The JAK/STAT Signaling Pathway as a Target/Panel Discussion
• Available Data on the Safety of JAK Inhibition: Rheumatology Experience/Panel Discussion
• Available and Emerging JAK Inhibitors in IBD: Clinical Trials, Populations, and Safety/Panel Discussion
• What’s New in IBD Care? Choosing Targets and Selecting Therapy
• The JAK/STAT Signaling Pathway as a Target/Panel Discussion
• Available Data on the Safety of JAK Inhibition: Rheumatology Experience/Panel Discussion
• Available and Emerging JAK Inhibitors in IBD: Clinical Trials, Populations, and Safety/Panel Discussion
Sponsored by the Academy for Continued Healthcare Learning (ACHL)
Supported by an educational grant from Gilead Sciences, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Completion of this activity including the pre and/or post assignments qualifies as a medium weight MIPS improvement activity under MACRA, and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Bruce Sands, MD, MS
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY
Joel Pekow, MD
Assistant Professor of Medicine, Section of Gastroenterology, Hepatology, and Nutrition
University of Chicago Medicine and Biological Sciences
Chicago, IL
Thomas Ullman, MD
Chief, Division of Gastroenterology
Montefiore Medical Center/Albert Einstein College of Medicine
Bronx, NY
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CE activity.
The following financial relationships have been provided:
Bruce Sands, MD, MS, (Chair)
Consulting Agreements: AbbVie, Allergan, Amgen, Inc., Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Celgene, Celltrion Healthcare, F. Hoffmann-La Roche Ltd., Ferring Pharmaceuticals, Gilead Sciences, Inc., Ironwood Pharmaceuticals, Inc, Janssen Pharmaceuticals, Inc., Lilly, Otsuka, Pfizer, Inc., Prometheus Laboratories Inc. , Salix Pharmaceuticals, Shire, Takeda, Theravance Biopharma R&D, Inc.
Grant/Research Support: Celgene
Honorarium Recipient: Takeda
Joel Pekow, MD, (Faculty)
Advisory Board: Janssen and Pfizer, Inc.
Consulting Agreement: Verastem
Grant Support: Takeda and AbbVie
Thomas Ullman, MD, (Faculty)
Advisory Board: Pfizer, Inc.
Honorarium Recipient: Janssen Pharmaceuticals, Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Tofacitinib, peficitinib, filgotinib, upadacitinib, and other JAK inhibitors under investigation for IBD
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 65% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org
For questions, contact Michelle Forcier at mforcier@achlcme.org
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.